Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Palmijihwang-tang (also known as Palmijihwang-hwan or PJH) is a traditional herbal medicine composed of eight medicinal herbs, including Rehmannia glutinosa and Aconitum carmichaelii. It is widely used in Korean and Chinese medicine, traditionally indicated for conditions associated with "kidney-yang deficiency." In the context of modern respiratory medicine, it has been investigated for its therapeutic potential in obstructive airway diseases such as asthma and chronic obstructive pulmonary disease (COPD). The formula exerts multi-target anti-inflammatory effects by significantly reducing levels of pro-inflammatory cytokines, particularly interleukin-13 (IL-13), tumor necrosis factor-alpha (TNF-α), and interleukin-6 (IL-6). Preclinical studies indicate that it suppresses the phosphorylation of NF-κB and ERK1/2 signaling pathways and inhibits airway remodeling by reducing the expression of matrix metalloproteinases (MMP-7, MMP-9) and transforming growth factor-beta (TGF-β).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on palmijihwang-tang.